Patients Out of Time, or POT, is a patient advocacy organization dedicated to educating public health professionals and the public about medical marijuana. Incorporated in 1995, the group is led by medical and nursing professionals and the five remaining participants in the federal government's Investigational New Drug program for cannabis. POT is a member organization of the Coalition for Rescheduling Cannabis. Cannabis sativa extract. ... Year 1995 (MCMXCV) was a common year starting on Sunday (link will display full 1995 Gregorian calendar). ... The Food and Drug Administrations Investigational New Drug (IND) program is the means by which a pharmaceutical company obtains permission to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved. ... Look up Cannabis in Wiktionary, the free dictionary. ... The Coalition for Rescheduling Cannabis is a U.S. organization founded circa 2002 to support removal of marijuana from Schedule I of the Controlled Substances Act. ...
POT Is the co-sponsor of a continuing series of medicinal cannabis conferences that are accredited for continuing education. See www.medicalcannabis.com for information about The Fifth National Clinical Conference on Cannabis Therapeutics to be held on the Monterey peninsula of California on April 4&5, 2008. The conference is co-sponsored by the California Nurses Association and the University of California, San Francisco, School of Medicine.
POT is a 501c3 educational charity and a corporation of the Commonwealth of Virginia.
Please see www.drugscience.org for information concerning the leadership of POT in the Coalition to Reschedule cannabis.
The discontinuation rate of combination therapy was as high as 30% among patients 60 and older with HCV infection, and patient age was significantly and inversely associated with the likelihood of adherence to combination therapy.
To assess whether patient age played a role in the efficacy and safety of combination therapy for chronic HCV, the investigators enrolled 208 consecutive patients with chronic HCV that was treatment naÃ¯ve.
The patients were treated with high-dose induction therapy with Intron A, consisting of six or 10 million units given by subcutaneous injection daily for two weeks, followed by the same dose three times per week for 22 weeks.
Share your thoughts, questions and commentary here
Want to know more? Search encyclopedia, statistics and forums:
Press Releases |
The Wikipedia article included on this page is licensed under the
Images may be subject to relevant owners' copyright.
All other elements are (c) copyright NationMaster.com 2003-5. All Rights Reserved.
Usage implies agreement with terms, 1022, m